Trypanosoma cruzi: Immunological predictors of benznidazole efficacy during experimental infection

Experimental Parasitology

Volumn 124, Issue 2, 2010, Pages 172-180

  Fernández, María C ^a   González Cappa, Stella M ^a   Solana, Maria E ^a  

^a Facultad de Medicina   (Argentina)

Author keywords

Benznidazole; IgG1; IgG2a; LT phenotypic analysis; Mice; Trypanosoma cruzi protozoan

Indexed keywords

BENZNIDAZOLE; CD69 ANTIGEN; HERMES ANTIGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; L SELECTIN;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHAGAS DISEASE; CONTROLLED STUDY; DRUG EFFICACY; EFFECTOR CELL; IMMUNOMODULATION; IMMUNOPHENOTYPING; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PARASITEMIA; PRIORITY JOURNAL; SPLENOMEGALY; SURVIVAL RATE; TRYPOMASTIGOTE;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, CD; ANTIGENS, CD44; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; CHAGAS DISEASE; DNA, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOGLOBULIN G; IMMUNOPHENOTYPING; MALE; MICE; MICE, INBRED C3H; MUSCLE, SKELETAL; NITROIMIDAZOLES; PARASITEMIA; POLYMERASE CHAIN REACTION; SPLEEN; T-LYMPHOCYTES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

ANIMALIA; MUS; PROTOZOA; TRYPANOSOMA CRUZI;

EID: 73449091142     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2009.09.006     Document Type: Article

References (52)

1. Andrade L.O., Machado C.R., Chiari E., Pena S.D., and Macedo A.M. Differential tissue distribution of diverse clones of Trypanosoma cruzi in infected mice. Molecular and Biochemical Parasitology 100 (1999) 163-172
2. Ávila H.A., Pereira J.B., Thiemann O., Paiva E., Degrave W., Morel C.M., and Simpson L. Detection of Trypanosoma cruzi in blood specimens of chronic chagasic patients by polymerase chain reaction amplification of kinetoplast minicircle DNA: comparison with serology and xenodiagnosis. Journal of Clinical Microbiology 31 (1993) 2421-2426
3. Bertocchi G.L., Álvarez M.G., Pérez D., Armenti A., Viotti R.J., Lococo B., Petti M., Postan M., Albareda M.C., Laucella S.A., and Tarleton R.L. Evaluación inmunológica del tratamiento con benznidazol en la enfermedad de Chagas crónica. Revista Argentina de Cardiología 76 (2008) 260-265
4. Brener Z., and Gazzinelli R.T. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. International Archives of Allergy and Immunology 114 (1997) 103-110
5. Buckner F.S., Wilson A.J., White T.C., and Van Voorhis W.C. Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrobial Agents and Chemotherapy 42 (1998) 3245-3250
6. + T central memory response in chronic Chagas disease. Nature Medicine 14 (2008) 542-550
7. + T-cell responses in the acute phase of Trypanosoma cruzi infection. Immunology 122 (2007) 584-595
8. Castro A.M., Luquetti A.O., Rassi A., Rassi G.G., Chiari E., and Galvão L.M. Blood culture and polymerase chain reaction for the diagnosis of the chronic phase of human infection with Trypanosoma cruzi. Parasitology Research 88 (2002) 894-900
9. Celentano A.M., and González Cappa S.M. In vivo macrophage function in experimental infection with Trypanosoma cruzi subpopulations. Acta Tropica 55 (1993) 171-180
10. Chiari E. Diagnostic tests for Chagas disease. In: Wendel S., Brener Z., Camargo M.E., and Rassi A. (Eds). Chagas Disease (American Trypanosomiasis): Its Impact on Transfusion and Clinical Medicine (1992), ISBT, São Paulo 153-164
11. Cordeiro F.D., Martins-Filho O.A., Da Costa Rocha M.O., Adad S.J., Correa-Oliveira R., and Romanha A.J. Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease. Clinical and Diagnostic Laboratory Immunology 8 (2001) 112-118
12. Coura J.R., Borges-Pereira J., Alves Filho F.I., Castro J.A., Cunha R.V., Costa W., and Junqueira A.C. Morbidade da doença de Chagas em áreas do sertão da Paraíba e da caatinga do Piauí. Revista da Sociedade Brasileira de Medicina Tropical 29 (1996) 197-205
13. Cunha-Neto E., Bilate A.M., Hyland K.V., Fonseca S.G., Kalil J., and Engman D.M. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity 39 (2006) 41-54
14. de Castro S. The challenge of Chagas' disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi. Acta Tropica 53 (1993) 83-98
15. Doenhoff M.J., Sabah A.A.A., Fletcher C., Webbe G., and Bain J. Evidence for an immune-dependent action of praziquantel on Schistosoma mansoni in mice. Transactions of the Society of Tropical Medicine and Hygiene 81 (1987) 947-951
16. Dos Reis G. Cell-mediated immunity in experimental Trypanosoma cruzi infection. Parasitology Today 13 (1997) 335-342
17. Dvorak J.A., and Howe C.L. The effects of Lampit (Bayer 2502) on the interaction of Trypanosoma cruzi with vertebrate cells in vitro. American Journal of Tropical Medicine and Hygiene 26 (1977) 58-63
18. Freilij H., Muller L., and González Cappa S.M. Direct micromethod for diagnosis of acute and congenital Chagas' disease. Journal of Clinical Microbiology 18 (1983) 327-330
19. Gazzinelli R., Pereira M.E., Romanha A., Gazzinelli G., and Brener Z. Direct lysis of Trypanosoma cruzi: a novel effector mechanism of protection mediated by human anti-gal antibodies. Parasite Immunology 13 (1991) 345-356
20. Gomes M.L., Macedo A.M., Vago R., Pena S.D.J., Galvão L.M.C., and Chiari E. Trypanosoma cruzi: optimization of polymerase chain reaction for detection in human blood. Experimental Parasitology 88 (1998) 28-33
21. González Cappa S.M., Chiale P., del Prado G.E., Katzin A.M., de Martini G.W., de Isola E.L.D., Abramo Orrego L., and Segura E.L. Isolation of a strain of Trypanosoma cruzi from a patient with chronic Chagas cardiomyopathy and its biological characterization. Medicina (Bs. Aires) 40 (1980) 63-68
22. Junqueira A.C.V., Chiari E., and Wincker P. Comparison of polymerase chain reaction with two classical parasitological methods for diagnosis of Chagas disease patients in a northeastern endemic region of Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene 90 (1996) 129-132
23. Marinho C.R.F., Nuñez-Apaza L.N., Martins-Santos R., Bastos K.R.B., Bombeiro A.L., Bucci D.Z., Sardinha L.R., Lima M.R.D., and Álvarez J.M. IFN-γ, but not nitric oxide or specific IgG, is essential for the in vivo control of low-virulence Sylvio X10/4 Trypanosoma cruzi parasites. Scandinavian Journal of Immunology 66 (2007) 297-308
24. Marinho C.R.F., D'Imperio Lima M.R., Grisotto M.G., and Alvarez J.M. Influence of acute-phase parasite load on pathology, parasitism, and activation of the immune system at the late chronic phase of Chagas' disease. Infection and Immunity 67 (1999) 308-318
25. + T cells in Trypanosoma cruzi infection. Immunological Reviews 201 (2004) 304-317
26. Martin D.L., and Tarleton R.L. Antigen-specific T cells maintain an effector memory phenotype during persistent Trypanosoma cruzi infection. Journal of Immunology 174 (2005) 1594-1601
27. Martins H.R., Figueiredo L.M., Valamiel-Silva J.C., Carneiro C.M., Machado-Coelho G.L., Vitelli-Avelar D.M., Bahia M.T., Martins-Filho O.A., Macedo A.M., and Lana M. Persistence of PCR-positive tissue in benznidazole-treated mice with negative blood parasitological and serological tests in dual infections with Trypanosoma cruzi stocks from different genotypes. Journal of Antimicrobial Chemotherapy 61 (2008) 1319-1327
28. Martins-Filho O.A., Eloi-Santos S.M., Teixeira-Carvalho A., Oliveira R.C., Rassi A., Luquetti A.O., Rassi G.G., and Brener Z. Double-blind study to evaluate flow cytometry analysis of anti-live trypomastigote antibodies for monitoring treatment efficacy in cases of human Chagas' disease. Clinical and Diagnostic Laboratory Immunology 9 (2002) 1107-1113
29. Martins-Filho O., Pereira M.E.S., Carvalho J.F., Cançado J.R., and Brener Z. Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease. Clinical and Diagnostic Laboratory Immunology 2 (1995) 569-573
30. Meira W.S.F., Galvão L.M.C., Gontijo E.D., Machado-Coelho G.L.L., Norris K.A., and Chiari E. Use of the Trypanosoma cruzi recombinant complement regulatory protein to evaluate therapeutic efficacy following treatment of chronic chagasic patients. Journal of Clinical Microbiology 42 (2004) 707-712
31. Mejía A.M., and Triana O. Genetic variability of Trypanosoma cruzi in blood and organs of infected mice determined by LSSP-PCR. Biomédica 25 (2005) 76-86
32. Mirkin G.A., Celentano A.M., Malchiodi E.L., Jones M., and González Cappa S.M. Different Trypanosoma cruzi strains promote neuromyopathic damage mediated by distinct T lymphocyte subsets. Clinical and Experimental Immunology 107 (1997) 328-334
33. Miyamoto C.T., Gomes M.L., Marangon A.V., de Araújo S.M., Bahia M.T., Martins-Filho O.A., de Lana M., and de Ornelas Toledo M.J. Usefulness of the polymerase chain reaction for monitoring cure of mice infected with different Trypanosoma cruzi clonal genotypes following treatment with benznidazole. Experimental Parasitology 120 (2008) 45-49
34. Murta S.M., and Romanha A.J. In vivo selection of population of Trypanosoma cruzi and clones resistant to benznidazole. Parasitology 116 (1998) 165-171
35. Murta S.M., Ropert C., Alves R.O., Gazzinelli R.T., and Romanha A.J. In-vivo treatment with benznidazole enhances phagocytosis, parasite destruction and cytokine release by macrophages during infection with a drug-susceptible but not with a derived drug-resistant Trypansoma cruzi population. Parasite Immunology 21 (1999) 535-544
36. + T-cell expansion and promotes resistance to reinfection. Antimicrobial Agents and Chemotherapy 46 (2002) 3790-3796
37. Piaggio E., Roggero E., Pitashny M., Wietzerbin J., Bottasso O.A., and Revelli S.S. Treatment with benznidazole and its immunomodulating effects on Trypanosoma cruzi-infected rats. Parasitology Research 87 (2001) 539-547
38. Rassi A., Amato Neto V., Siqueira A.F., Filho F.F., Amato V.S., and Rassi Junior A. Efeito protetor do benznidazol contra a reativação parasitária em pacientes cronicamente infectados pelo Trypanosoma cruzi e tratados com corticóides em virtude de afecções secundárias. Revista da Sociedade Brasileira de Medicina Tropical 32 (1999) 475-482
39. Rhalem A., Sahibi H., Lasri S., and Jaffe C.L. Analysis of immune responses in dogs with canine visceral leishmaniosis before, and after, drug treatment. Veterinary Immunology and Immunopathology 71 (1999) 69-76
40. Rodriguez A.M., Santero F., Afchain D., Bazin H., and Capron A. Trypanosoma cruzi infection in B-cell-deficient rats. Infection and Immunity 31 (1981) 524-529
41. Romanha A.J., Alves R.O., Murta S.M.F., Silva J.S., Ropert C., and Gazzinelli R.T. Experimental chemotherapy against Trypanosoma cruzi infection: role of endogenous interferon-γ in mediating parasitologic cure. The Journal of Infectious Diseases 186 (2002) 823-828
42. Sathler-Avelar R., Vitelli-Avelar D.M., Massara R.L., Borges J.D., Lana M., Teixeira-Carvalho A., Dias J.C., Elói-Santos S.M., and Martins-Filho O.A. Benznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile. Scandinavian Journal of Immunology 64 (2006) 554-563
43. Solana M.E., Celentano A.M., Tekiel V.S., Jones M., and González Cappa S.M. Trypanosoma cruzi: effect of parasite subpopulations on murine pregnancy outcome. Journal of Parasitology 88 (2002) 102-106
44. Solari A., Ortiz S., Soto A., Arancibia C., Campellay R., Contreras M., Salinas P., Royas A., and Schinone H. Treatment of Trypanosoma cruzi infected children with nifurtimox: a 3 year follow-up by PCR. Journal of Antimicrobial Chemotherapy 48 (2001) 515-519
45. Sztein M.B., and Kierszenbaum F. Mechanisms of development of immunosuppression during Trypanosoma infections. Parasitology Today 9 (1993) 424-428
46. Targett G.A. Chemotherapy and the immune response in parasitic infections. Parasitology 90 (1985) 661-673
47. + T cells increases susceptibility and reverses vaccine-induced immunity in mice infected with Trypanosoma cruzi. Journal of Immunology 114 (1990) 717-724
48. The Special Programme for Research and Training in Tropical Diseases (TDR), 2007. Reporte sobre la enfermedad de Chagas. Grupo de trabajo científico 17-20 de abril de 2005 - Actualizado en julio de 2007. Buenos Aires, Argentina. Guhl F., Lazdins-Helds J.K. (Eds.). p. 97.
49. Villarreal D., Nirde P., Hide M., Barnabe C., and Tibayrenc M. Differential gene expression in benznidazole-resistant Trypanosoma cruzi parasites. Antimicrobial Agents and Chemotherapy 49 (2005) 2701-2709
50. Voller A., Drapper D.C., Bidwell D.E., and Bartlett A. Microplate enzyme linked immunosorbent assay for Chagas' disease. Lancet 1 (1975) 426-429
51. World Health Organization (WHO), 2002. WHO Technical Report Series No. 905. Control of Chagas' Disease. Geneva.
52. Zulantay I., Honores P., Solari A., Apt W., Ortiz S., Osuna A., Rojas A., López B., and Sanches G. Use of polymerase chain reaction (PCR) and hybridization assays to detect Trypanosoma cruzi in chronic chagasic patients treated with itraconazole or allopurinol. Diagnostic Microbiology and Infectious Disease 48 (2004) 253-257